Avalyn Pharma logo

Avalyn Pharma

Seattle, WA

Avalyn Pharma Inc. operates as a pharmaceutical company. The Company develops treatments for Idiopathic Pulmonary Fibrosis (IPF).

avalynpharma.com

Company Details

Founded

2011

Employees

Between 10 - 50 employees

Raised

$436,679,488

Headquarters Location

Seattle, WA

Public

No

Acquired

No

CEO

Lyn BaranowskiLyn Baranowski

Founders

Richard Vincent
Richard Vincent
Mark Surber

Company Collections

These are collections Avalyn Pharma is a part of. Click on the collection name to view similar companies.

Avalyn Pharma's Industries

Avalyn Pharma's Tech Stack

Current Job Listings

Listing 0 of 3 job openings

    Avalyn Pharma Headquarters Location

    701 Pike St suite 1500, Seattle, WA 98101

    Total Amount Raised: $436,679,488

    Avalyn Pharma Funding Rounds

    • Series D

      $100,000,000

      Series D Investors

      Sr One
      Suvretta Capital Management
      Pivotal bioVenture Partners
      TPG Biotech
      Wellington Management
      Eventide
      Surveyor Capital
      F-Prime Capital
      RiverVest Venture Management
      Norwest Venture Partners
      Rock Springs Capital
      Vida Ventures
      Catalio Capital Management
      Perceptive Advisors
      Novo Holdings
      Hamilton Square Partners Management
      T. Rowe Price
      Piper Heartland Healthcare Capital

    • Series C

      $175,000,000

      Series C Investors

      Eventide
      Perceptive Advisors
      Sr One
      Wellington Management
      Catalio Capital Management
      Piper Heartland Healthcare Capital
      Vida Ventures
      Pivotal bioVenture Partners
      Surveyor Capital
      Rock Springs Capital
      RiverVest Venture Management
      Norwest Venture Partners
      F-Prime Capital
      Novo Holdings

    • Series B

      $35,500,000

      Series B Investors

      Norwest Venture Partners
      F-Prime Capital
      Pivotal bioVenture Partners
      TPG Biotech
      RiverVest Venture Management
      Novo Holdings

    • Series A

      $62,000,000

      Series A Investors

      Andera Partners
      F-Prime Capital
      Novo Holdings
      RiverVest Venture Management
      TPG Biotech

    • Series A

      $62,000,000

      Series A Investors

      Eight Roads
      Andera Partners
      RiverVest Venture Management
      TPG Biotech
      F-Prime Capital
      Novo Holdings
      Edmond de Rothschild Suisse

    • Seed

      $2,179,480

    Funding info provided by Diffbot.

    Avalyn Pharma Reviews

    0 out of 5 stars

    Based on 0 reviews

    Review data

    Share your thoughts

    Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Avalyn Pharma.

    Recent reviews